Plain-English translation of NCT06496191 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether fecal microbiota transplantation ()—a treatment where healthy gut bacteria are transferred into your digestive system—can help reduce alcohol cravings and support sobriety in people with alcohol-related liver cirrhosis. Half of participants will receive along with standard alcohol counseling and a medication called baclofen, while the other half will receive a placebo (inactive treatment) plus the same counseling and medication. The study lasts one year and involves 54 participants total.
Alcohol use disorder and liver cirrhosis are serious conditions, and current treatments don't work for everyone. Recent research suggests that alcohol affects the balance of bacteria in your gut, which in turn may increase cravings and make relapse more likely. This trial is testing whether restoring healthy gut bacteria could be a new way to help people stay sober and manage their condition.
If you qualify, you'll be randomly assigned to one of two groups. Both groups will receive alcohol counseling and the medication baclofen to help reduce cravings. One group will also receive the gut bacteria transplant () delivered through a tube passed down the throat during a procedure on day 4, while the other group will receive a placebo. You'll visit the clinic regularly over the course of one year so doctors can monitor your progress, measure your alcohol use, and check your health.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
India